Effects of adjuvant aromatase inhibitor therapy on lipid profiles

Expert Review of Anticancer Therapy

Volumn 6, Issue 11, 2006, Pages 1653-1662

  Monnier, Alain ^a  

^a Centre Hospitalier General Andre Boulloche   (France)

Author keywords

Anastrozole; Aromatase inhibitors; Exemestane; Hormonal therapy; Letrozole; Lipid levels; Tamoxifen

Indexed keywords

ACETYLSALICYLIC ACID; ANASTROZOLE; ANTILIPEMIC AGENT; AROMATASE INHIBITOR; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; EXEMESTANE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LETROZOLE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; QUINAPRIL; TAMOXIFEN;

BEHAVIOR MODIFICATION; BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; LIFESTYLE; LIPID BLOOD LEVEL; MENOPAUSAL SYNDROME; NONHUMAN; PATIENT MONITORING; REVIEW; SIDE EFFECT; STROKE; THROMBOEMBOLISM; TRIACYLGLYCEROL BLOOD LEVEL;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CARDIOVASCULAR SYSTEM; CHEMOTHERAPY, ADJUVANT; CHOLESTEROL; FEMALE; HUMANS; LIPIDS; MENOPAUSE; NEOPLASMS; TAMOXIFEN;

EID: 33845361860     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.11.1653     Document Type: Review

References (94)

1. Jacobs D, Blackburn H, Higgins M et al. Report of the Conference on Low Blood Cholesterol: mortality associations. Circulation 86, 1046-1060 (1992).
2. Kritchevsky SB. Dietary lipids and the low blood cholesterol-cancer association. Am. J. Epidemiol. 135, 509-520 (1992).
3. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. Br Med. J. 308, 373-379 (1994).
4. Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res. 59, 4493-4501 (1999).
5. Herman DR, Ganz PA, Petersen L, Greendale GA. Obesity and cardiovascular risk factors in younger breast cancer survivors: the Cancer And Menopause Study (CAMS). Breast Cancer Res. Treat. 93, 13-23 (2005).
6. Adami HO. Long-term consequences of estrogen and estrogen-progestin replacement. Cancer Causes Control 3, 83-90 (1992).
7. Nabulsi AA, Folsom AR, White A et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N. Engl. J. Med. 328, 1069-1075 (1993).
8. Grodstein F, Stampfer MJ, Manson JE et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N. Engl. J. Med. 335, 453-461 (1996). Erratum in: N. Engl. J. Med. 335, 1406 (1996).
9. Lip GY, Blann AD, Jones AF, Beevers DG. Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. Am. Heart J. 134, 764-771 (1997).
10. Bundred NJ. The effects of aromatase inhibitors on lipids and thrombosis. Br. J. Cancer 93(Suppl. 1), S23-S27 (2005).
11. Howell A, Cuzick J. Vascular effects of aromatase inhibitors: data from clinical trials. J. Steroid Biochem. Mol. Biol. 95, 143-149 (2005).
12. Womens Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Womens Health Initiative Randomized Trial. JAMA 291, 1701-1712 (2001).
13. Writing Group for the Womens Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288, 321-333 (2002).
14. Matthews KA, Wing RR, Kuller LH, Meilahn EN, Plantinga P. Influence of the perimenopause on cardiovascular risk factors and symptoms of middle-aged healthy women. Arch. Intern. Med. 154, 2349-2355 (1994).
15. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 98, 83-90 (1993).
16. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann. Oncol. 16, 1569-1583 (2005).
17. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J. Clin. Oncol. 23, 619-629 (2005).
18. Kannel WB, Wilson PW. Comparison of risk profiles for cardiovascular events: implications for prevention. Adv. Intern. Med. 42, 39-66 (1997).
19. Miller-Bass K, Newschaffer CJ, KIag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch. Intern. Med. 53, 2209-2216 (1993).
20. Davidson MH, Maki KC, Karp SK, Ingram KA. Management of hypercholesterolaemia in postmenopausal women. Drugs Aging 19, 169-178 (2002).
21. Korhonen T, Savolainen MJ, Ikäheimo M, Linnaluoto MK, Kervinen K, Kesäniemi VA. Association of lipoprotein cholesterol and triglycerides with the severity of coronary artery disease in men and women. Atherosclerosis 127, 213-220 (1996).
22. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102, 1082-1085 (2000).
23. American Heart Association. Heart disease and stroke statistics - 2005 update. Dallas, Tex: National Center; January (2005).
24. Genest J, Frohlich J, Fodor G, McPherson R; Working Group on Hypercholesterolemia and Other Dyslipidermias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. Can. Med. Ass. J. 169, 921-924 (2003). Erratum in Can. Med. Ass. J. 169, 1149 (2003).
25. National Institutes of Health. Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. Bethesda, MD. National Heart, Lung and Blood Institute. NIH Publication 02-5215 September (2002).
26. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am. Heart J. 114, 413-419 (1987).
27. La Rosa JC. Triglycerides and coronary risk in women and the elderly. Arch. Intern. Med. 157, 961-968 (1997).
28. Costa J, Borges M, David C, Carneiro AV. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. Br. Med. J. 332, 1115-1124 (2006).
29. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br. Med. J. 326, 1423 (2003).
30. Hebert PR, Gaziano JM, Chan KS et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 278, 313-321 (1997).
31. Chlebowski RT, Anderson GL, Geller M, Col N. Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use. Clin. Breast Cancer 6(Suppl. 2), S58-S64 (2006).
32. Kusama M, Kaise H, Nakayama S, Ota D, Misaka T, Aoki T. Crossover trial for lipid abnormality in postmenopausal breast cancer patients during selective estrogen receptor modulators (SERMs) administrations. Breast Cancer Res. Treat. 88, 1-16 (2004).
33. Thangaraju M, Kumar K, Gandhirajan R, Sachdanandam P. Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer. Cancer 73, 659-663 (1994).
34. Grainger DJ, Schofield PM. Tamoxifen for the prevention of myocardial infarction in humans: preclinical and early clinical evidence. Circulation 112, 3018-3024 (2005).
35. Gylling H, Pyrhonen S, Mantyla E, Maenpaa H, Kangas L, Miettinen TA. Tamoxifen and toremifene lower serum cholesterol by inhibition of δ 8-cholesterol conversion to lathosterol in women with breast cancer. J. Clin. Oncol. 13, 2900-2905 (1995).
36. Holleran AL, Lindenthal B, Aldaghlas TA, Kelleher JK. Effect of tamoxifen on cholesterol synthesis in HepG2 cells and cultured rat hepatocytes. Metabolism 47, 1504-1513 (1998).
37. de Medina P, Payre BL, Bernad J et al. Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells. J. Pharmacol. Exp. Ther. 308, 1165-1173 (2004).
38. Herrington DM, Klein KP. Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. Womens Health Issues 11, 95-102 (2001).
39. Love RR, Wiebe DA, Newcomb PA et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann. Intern. Med. 115, 860-864 (1991).
40. Saarto T, Blomqvist C, Ehnholm C, Taskinen MR, Elomaa I. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J. Clin. Oncol. 14, 429-433 (1996).
41. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J. Natl Cancer Inst. 86, 1534-1539 (1994).
42. Grey AB, Stapleton JP, Evans MC, Reid IR. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin. Endocrinol. Metab. 80, 3191-3195 (1995).
43. Decensi A, Bonanni B, Guerrieri-Gonzaga A et al. Biologic activity of tamoxifen at low doses in healthy women. J. Natl Cancer Inst. 90, 1461-1467 (1998).
44. Elisaf M, Bairaktari E, Nicolaides C et al. The beneficial effect of tamoxifen on serum lipoprotein-A levels: an additional anti-atherogenic property. Anticancer Res. 16, 2725-2728 (1996).
45. Dziewulska-Bokiniec A, Wojtacki J, Skokowski J, Kortas B. The effect of tamoxifen treatment on serum cholesterol fractions in breast cancer women. Neoplasma 41, 13-16 (1994).
46. Brun LD, Gagne C, Rousseau C, Moorjani S, Lupien PJ. Severe lipidemia induced by tamoxifen. Cancer 57, 2123-2126 (1986).
47. Law MR, Thompson SG, Wald NJ: Assessing possible hazards of reducing serum cholesterol. Br. Med. J. 308, 373-379 (1994).
48. Nordenskjold B, Rosell J, Rutqvist LE et al. Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. J. Natl Cancer Inst. 97, 1609-1610 (2005).
49. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J. Natl Cancer Inst. 185, 1398-1406 (1993).
50. McDonald CC, Alexander FE, Whyte BW et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. Br. Med. J. 311, 977-980 (1995).
51. Braithwaite RS, Chlebowski RT, Lau J et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J. Gen. Intern. Med. 18, 937-947 (2003).
52. Roe EB, Chiu KM, Arnaud CD. Selective estrogen receptor modulators and postmenopausal health. Adv. Intern. Med. 45, 259-278 (2000).
53. Esteva FJ, Hortobagyi GN. Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women. Breast 15, 301-312 (2006).
54. Hozumi Y, Hakamata Y, Sasanuma H, Ogura S, Nagai H. Effects of anastrozole on lipid metabolism compared with tamoxifen in rats. Breast Cancer Res. Treat. 76, 131-136 (2002).
55. Goss PE, Qi S, Hu H et al. The effects of atamestane, toremifene, and atamestane plus toremifene compared to letrozole on bone, serum lipids and uterus. Proc. Am. Soc. Clin. Oncol. 23 (S16), 28S (2005) (Abstract 600).
56. Goss PE, Qi S, Cheung AM, Hu H, Mendes M, Pritzker KP. Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin. Cancer Res. 10, 5717-5723 (2004).
57. Wojtacki J, Lesniewski-Kmak K, Pawlak W, Nowicka E. Anastrozole therapy and lipid profile: an update, Eur. J. Cancer 142(Suppl. 2), 142 (2004) (Abstract 297).
58. Elisaf MS, Bairaktari ET, Nicolaides C et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur. J. Cancer 37, 1510-1513 (2001).
59. Tafesh G, Tafesh J, Chetuver L, Shnaider J, et al. Effects of letrozole on plasma lipids, triglycerides and estradiol in women with metastatic breast cancer 2006. Ann. Oncol. 17(Suppl. 9). IX77 (2006) (Abstract 173P).
60. Engan T, Krane J. Johannessen DC, Lønning PE, Kvinnsland S. Plasma changes in breast cancer patients during endocrine therapy - lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Res. Treat 36, 287-297 (1995).
61. Atalay G, Dirix L, Biganzoli L et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized Phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Ann. Oncol. 5, 211-217 (2004).
62. Sawada S, Sato K. Effect of anastrozole and tamoxifen on serum lipid levels in Japanese postmenopausal women with early breast cancer. Breast Cancer Res. Treat. 82(Suppl. 1), S31-S32 (2003).
63. Sawada S, Sato K, Kusuhara M et al. Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer. Acta Oncol. 44, 134-141 (2005).
64. Howell A, Cuzick J, Baum M et al. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60-62 (2005).
65. Arimidex®, package insert. AstraZeneca Pharmaceuticals LP, DE, USA (2005).
66. Boccardo F, Rubagotti A, Puntoni M et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J. Clin. Oncol. 23, 5138-5147 (2005).
67. Hori Y, Akizuki M, Nishimura R. Comparison of adverse effects of lipid metabolism of anastrozole with tamoxifen in adjuvant setting for postmenopausal women with early breast cancer. Eur. J. Cancer 4 (Suppl.), 94 (2006) (Abstract 172).
68. Thürlimann B, on behalf of the BIG 1-98 Collaborative Group. A randomized trial of letrozole compared to tamoxifen in postmenopausal women endocrine-responsive with early-stage breast cancer. N. Engl. J. Med. 353, 2747-2757 (2005).
69. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N. Engl. J. Med. 350, 1081-1092 (2004). Erratum in N. Engl. J. Med. 351, 2461 (2004).
70. Coombes RC, Paridaens R, Jassem J et al. First mature analysis of the Intergroup Exemestane Study. Proc. Am. Soc. Clin. Oncol. 24(S18), S933 (2006) (Abstract LBA 527).
71. Markopoulos C, Polychronis A, Zobolas V et al. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res. Treat. 93; 61-66 (2005).
72. Love RR, Hutson PR, Havighurst TC, Cleary JF. Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer. Clin. Cancer Res. 11, 1500-1503 (2005).
73. Harper-Wynne C, Ross G, Sacks N et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol. Biomarkers Prev 11, 614-621 (2002).
74. Heshmati HM, Khosla S, Robins SP et al. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J. Bone Miner. Res. 17, 172-178 (2002).
75. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349, 1793-1802 (2003).
76. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17. J. Natl Cancer Inst. 97, 1262-1271 (2005).
77. Kaufmann M, Rody A. Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy. J. Cancer Res. Clin. Oncol. 131, 487-494 (2005).
78. Wasan KM, Goss PE, Pritchard PH et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA. 17L). Ann. Oncol. 16, 707-715 (2005).
79. Markopoulos C, Chrissochou M, Michailidou A et al. Effect of exemestane on the lipidemic profile of postmenopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy. Anti-Cancer Drug, 16, 879-833 (2005).
80. Krag LE, Geisler J, Lonning PE et al. Lipid and coagulation profile in postmenopausal women with early breast cancer at low risk treated with exemestane: a randomized, placebo-controlled study [abstract]. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J. Clin. Oncol. 22(Suppl. 5), S14 (2004) (Abstract 650).
81. Lønning PE, Geisler J, Krag L et al. Lipid profile and homocysteine levels in postmenopausal women with early breast cancer at low risk treated for two years with exemestane: follow-up results of a randomized, placebo-controlled study. Proceedings of the 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA (2005) (Abstract 4108).
82. Nygard O, Vouset SE, Refsum H et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 274, 1526-1533 (1995).
83. Refsum H, Nurk E, Smith AD et al. The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. J. Nutr. 136, S1731-S1740 (2006).
84. McCloskey E, Eastell R, Lakner G, Miyamoto A, Clack G. Initial results from the LEAP study: the first direct comparison of safety parameters between aromatase inhibitors in healthy postmenopausal women. Proceedings of the 28th Annual San Antonio Breast Cancer Symposium. San Antonio, TX (USA). (2005) (Abstract 2052).
85. Sniderman AD, Furberg CD, Keech A et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361, 777-780 (2003).
86. Michalaki V, Koutroulis G, Syrigos K, Piperi C, Kalofoutis A. Evaluation of serum lipids and high-density lipoprotein subfractions (HDL2, HDL3) in postmenopausal patients with breast cancer. Mol. Cell. Biochem. 268, 19-24 (2005).
87. Repetto L, Vannozzi O, Hazini A, Sestini A, Pietropaolo M, Rosso R. Anastrozole and quinapril can be safely coadministered to elderly women with breast cancer and hypertension: a pharmacokinetic study. Ann. Oncol. 14, 1587-1588 (2003).
88. Grundy SM, Cleeman JI, Merz CN et al, Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler. Thromb. Vasc. Biol. 24, E149-E161 (2004).
89. Sposito AC, Mansur AP, Maranhao RC, Martinez TR, Aldrighi JM, Ramires JA. Triglyceride and lipoprotein (a) are markers of coronary artery disease severity among postmenopausal women. Maturitas 39, 203-208 (2001).
90. Goss PE, Ingle JN, Palmer MJ, Shepherd LE, Tu D. Updated analysis of NCIC CTG MA. 17 (letrozole vs placebo to letrozole vs placebo) post unblinding. Proceedings of the 28th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA December 8-11, 2005 (Abstract 16).
91. De Boer R, Burris A, Monnier A et al. On behalf of the H2H trial steering committee. The Head to Head trial: letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer. Proc. Am. Soc. Clin. Oncol. 24(S18), S582 (Abstract 10672).
92. Sestak I, Kealy R, Edwards R, Howell A, Forbes J, Cuzick J. Internation breast cancer intervention study I: updated side effects analysis. Eur. J. Cancer 4 (Suppl.), 48 (2006) (Abstract 11).
93. Wickerman L, Fourchotte V. The NSABP's second breast cancer prevention study, the STAR trial. Eur. J. Cancer 4(Suppl.), 47 (2006) (Abstract 10).
94. Bruning PF, Bonfrer JM, Hart AA et al. Tamoxifen, serum lipoproteins and cardiovascular risk. Br. J. Cancer 58, 497-499 (1988).